药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
3,7,11,15-tetramethyl-hexadecan-1-ol
Fulranumab
The risk or severity of adverse effects can be increased when Fulranumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Patritumab
The risk or severity of adverse effects can be increased when Patritumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Lorvotuzumab mertansine
The risk or severity of adverse effects can be increased when Lorvotuzumab mertansine is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Urelumab
The risk or severity of adverse effects can be increased when Urelumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Visilizumab
The risk or severity of adverse effects can be increased when Visilizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Gantenerumab
The risk or severity of adverse effects can be increased when Gantenerumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Benralizumab
The risk or severity of adverse effects can be increased when Benralizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ocrelizumab
The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Anifrolumab
The risk or severity of adverse effects can be increased when Anifrolumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Rilotumumab
The risk or severity of adverse effects can be increased when Rilotumumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Crenezumab
The risk or severity of adverse effects can be increased when Crenezumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Avelumab
The risk or severity of adverse effects can be increased when Avelumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Varlilumab
The risk or severity of adverse effects can be increased when Varlilumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Lebrikizumab
The risk or severity of adverse effects can be increased when Lebrikizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Vadastuximab Talirine
The risk or severity of adverse effects can be increased when Vadastuximab Talirine is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Romosozumab
The risk or severity of adverse effects can be increased when Romosozumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Landogrozumab
The risk or severity of adverse effects can be increased when Landogrozumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Seribantumab
The risk or severity of adverse effects can be increased when Seribantumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ligelizumab
The risk or severity of adverse effects can be increased when Ligelizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ublituximab
The risk or severity of adverse effects can be increased when Ublituximab is combined with Belantamab mafodotin.